FDA Letter API

reBreathe Vapor Products

Letter data

Company
reBreathe Vapor Products
Recipient
Debbra Warren | reBreathe Vapor Products | United States | (b)(6)
Issue date
2022-05-27
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Tobacco
CMS ID
617043
Reference number
RW2101626
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: 21-CFR-PART-114021-CFR-PART-1141

21 U.S.C.: 21-USC-301

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER reBreathe Vapor Products MARCS-CMS 617043 — May 27, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: RW2101626 Product: Tobacco Recipient: Recipient Name Debbra Warren reBreathe Vapor Products United States (b)(6) Issuing Office: Center for Tobacco Products United States Dear Debbra Warren: The United States Food and Drug Administration’s (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions included in your response dated August 29, 2021 in response to our Warning Letter dated August 20, 2021. Based on our evaluation, it appears that you have taken steps to address the violations contained in the Warning Letter regarding your website https://rebreathevapor.com. However, our surveillance shows you continue to offer for sale to customers in the United States other tobacco products that may be subject to market authorization requirements. FDA encourages you to discuss with your suppliers the current status of any particular tobacco product’s marketing application or any product’s marketing authorization. For additional information regarding currently marketed tobacco products that a company generally might manufacture, distribute, or sell without risking FDA enforcement, please visit our website https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/deemed-new-tobacco-product-applications-lists?utm_medium=email&utm_source=govdelivery#list%20of%20deemed. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with each applicable provision of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA’s implementing regulations or with other relevant legal authority. Please note that if your firm is found to be in violation of the FD&C Act, 21 U.S.C.§ 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143 in the future, this may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and/or injunction. Sincerely, /S/ David Rice Branch Chief Division of Promotion, Advertising, and Labeling Office of Compliance and Enforcement Center for Tobacco Products VIA Electronic Mail cc: Plush n’ Rich, LLC Attn: Aaron Jasper aaronjasper20@gmail.com GoDaddy.com, LLC abuse@godaddy.com Content current as of: 06/02/2022 Regulated Product(s) Tobacco